Get the Stockscreener App
1.795
0.56%
-0.005
Artiva Biotherapeutics Inc stock is traded at $1.795, with a volume of 54,892.
It is down -0.56% in the last 24 hours and down -11.82% over the past month.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
See More
Previous Close:
$1.80
Open:
$1.82
24h Volume:
54,892
Relative Volume:
0.18
Market Cap:
$47.75M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-8.67%
1M Performance:
-11.82%
6M Performance:
-82.05%
1Y Performance:
+0.00%
1-Day Range:
$1.79
$1.90
1-Week Range:
$1.79
$2.15
52-Week Range:
$1.78
$17.31
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
Name
Artiva Biotherapeutics Inc
Sector
Industry
Phone
(858) 267-4467
Address
5505 MOREHOUSE DRIVE, SAN DIEGO
Compare ARTV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARTV
Artiva Biotherapeutics Inc
|
1.79 | 47.75M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.75 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
517.19 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
316.48 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
544.13 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.37 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Resumed | H.C. Wainwright | Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-13-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Initiated | Jefferies | Buy |
| Aug-13-24 | Initiated | Needham | Buy |
| Aug-13-24 | Initiated | TD Cowen | Buy |
| Aug-13-24 | Initiated | Wedbush | Outperform |
View All
Artiva Biotherapeutics Inc Stock (ARTV) Latest News
Bank of America Corp DE Sells 7,001 Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Brokers Set Expectations for ARTV Q2 Earnings - Defense World
Artiva Biotherapeutics (NASDAQ:ARTV) Upgraded by HC Wainwright to Buy Rating - Defense World
Artiva Biotherapeutics (NASDAQ:ARTV) Coverage Initiated by Analysts at HC Wainwright - Defense World
Brokers Offer Predictions for ARTV FY2026 Earnings - Defense World
Promising Advancements and Financial Strength Position Artiva Biotherapeutics for Significant Upside - TipRanks
Artiva Biotherapeutics assumed with a Buy at H.C. Wainwright - TipRanks
NK Cell Therapy Pipeline 2025: Latest FDA Approvals, Clinical - openPR.com
Deutsche Bank AG Takes Position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Shares Bought by BNP Paribas Financial Markets - Defense World
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Rating of “Buy” from Analysts - Defense World
Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire
Reviewing Bio-Techne (NASDAQ:TECH) and Artiva Biotherapeutics (NASDAQ:ARTV) - Defense World
Needham & Company LLC Issues Pessimistic Forecast for Artiva Biotherapeutics (NASDAQ:ARTV) Stock Price - Defense World
Research Analysts Offer Predictions for ARTV FY2025 Earnings - Defense World
Artiva Biotherapeutics Reports Q1 2025 Progress - MSN
Artiva Biotherapeutics announces new, long-term data for AlloNK combination - TipRanks
Artiva Biotherapeutics Reports Promising Phase 1/2 Data for AlloNK® in Combination with Rituximab for Heavily Pretreated B-cell Non-Hodgkin Lymphoma Patients - Nasdaq
Artiva reports promising AlloNK therapy results in B-NHL study - Investing.com
Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting - GlobeNewswire
Artiva Biotherapeutics, Inc. Announces Longer-Term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK®? in Combination with Rituximab in Patients with B-Cell-Cell- Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting - marketscreener.com
Artiva Biotherapeutics: Strategic Delay and Expanded Research Justify Buy Rating - TipRanks
Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights - GlobeNewswire
Artiva Biotherapeutics, Inc.: Strategic Advancements and Market Potential in Biotherapeutics Highlighted by Phase IIa Trial Initiation and FDA Clearance - TipRanks
Artiva Biotherapeutics, Inc. SEC 10-Q Report - TradingView
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
JPMorgan Chase & Co. Acquires 26,893 Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Shares Acquired by Geode Capital Management LLC - Defense World
Artiva Biotherapeutics Announces Promising Data for AlloNK® + Rituximab in B-cell Driven Diseases Ahead of ASGCT 28th Annual Meeting - Nasdaq
Artiva Biotherapeutics to Present Longer-term Phase 1/2 - GlobeNewswire
Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting - Yahoo Finance
NK Cell Therapy Therapeutics Market Size in 7MM is expected - openPR.com
Norges Bank Buys New Stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Norges Bank Makes New Investment in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - The AM Reporter
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Artiva Biotherapeutics’ (ARTV) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Promising Outlook for Artiva Biotherapeutics Amid Strategic Manufacturing and Regulatory Support - TipRanks
Artiva Biotherapeutics names new Chief Medical Officer By Investing.com - Investing.com South Africa
Artiva Biotherapeutics Names New Chief Medical Officer - marketscreener.com
Artiva Biotherapeutics names new Chief Medical Officer - Investing.com Australia
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer - GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday SessionAgilon Health (NYSE:AGL), Alumis (NASDAQ:ALMS) - Benzinga
Artiva Biotherapeutics (ARTV) – Investment Analysts’ Recent Ratings Changes - Defense World
12 Health Care Stocks Moving In Monday's Intraday SessionAditxt (NASDAQ:ADTX), Alumis (NASDAQ:ALMS) - Benzinga
Artiva Biotherapeutics Reports 2024 Financial Results - TipRanks
Artiva Biotherapeutics’ SWOT analysis: NK cell therapy stock faces pivotal year - Investing.com Canada
Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Artiva Biotherapeutics’ SWOT analysis: NK cell therapy stock faces pivotal year By Investing.com - Investing.com South Africa
Artiva Biotherapeutics Inc Stock (ARTV) Financials Data
There is no financial data for Artiva Biotherapeutics Inc (ARTV). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Artiva Biotherapeutics Inc Stock (ARTV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| 5AM Partners VI, LLC | 10% Owner |
Jul 22 '24 |
Buy |
12.00 |
833,333 |
9,999,996 |
1,182,054 |
| venBio Global Strategic Fund I | 10% Owner |
Jul 22 '24 |
Buy |
12.00 |
416,666 |
4,999,992 |
1,936,637 |
| GC Corp. | 10% Owner |
Jul 22 '24 |
Buy |
12.00 |
1,666,666 |
19,999,992 |
3,306,900 |
| GC Corp. | 10% Owner |
Jul 22 '24 |
Buy |
12.00 |
416,666 |
4,999,992 |
1,260,512 |
| Huh Yong-Jun | Director |
Jul 22 '24 |
Buy |
12.00 |
2,083,332 |
24,999,984 |
3,306,900 |
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):